Keros Therapeutics, Inc. Income Taxes Receivable, Current
Keros Therapeutics, Inc. (KROS) had Income Taxes Receivable, Current of $2.25 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes
us-gaap:IncomeTaxesReceivable · last filed 2026-08-03
- 2026-06-30: Income Taxes Receivable, Current $2.25M.
- 2026-03-31: Income Taxes Receivable, Current $2.25M.
- 2025-12-31: Income Taxes Receivable, Current $2.25M.
- 2024-12-31: Income Taxes Receivable, Current $0.00.
| Period end | Income Taxes Receivable, Current |
|---|---|
| 2026-06-30 | $2.25M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $2.25M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $2.25M 10-Q · filed 2026-08-03 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-04 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-03 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-04 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-05 |
| 2021-12-31 | $30.00K 10-K · filed 2023-03-03 |
| 2021-09-30 | $24.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-05 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 |
| 2020-12-31 | $172.00K 10-K · filed 2022-03-09 |
| 2020-09-30 | $172.00K 10-Q · filed 2020-11-10 |
| 2020-06-30 | $172.00K 10-Q · filed 2020-08-13 |
| 2020-03-31 | $172.00K 10-Q · filed 2020-05-22 |
| 2019-12-31 | $0.00 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |